Cited 17 times in
Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김중선 | - |
dc.contributor.author | 박세일 | - |
dc.contributor.author | 오재원 | - |
dc.contributor.author | 이용호 | - |
dc.contributor.author | 홍그루 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 이오현 | - |
dc.contributor.author | 이찬주 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 이용준 | - |
dc.contributor.author | 전옥희 | - |
dc.contributor.author | 이슬기 | - |
dc.date.accessioned | 2022-12-22T03:46:40Z | - |
dc.date.available | 2022-12-22T03:46:40Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191983 | - |
dc.description.abstract | Background: Recent studies have reported improved diastolic function in patients administered sodium-glucose cotransporter 2 inhibitors (SGLT2i). We aimed to investigate the effect of dapagliflozin on left ventricular (LV) diastolic function in a diabetic animal model and to determine the molecular and cellular mechanisms underlying its function. Methods: A total of 30 male New Zealand white rabbits were randomized into control, diabetes, or diabetes+dapagliflozin groups (n = 10/per each group). Diabetes was induced by intravenous alloxan. Cardiac function was evaluated using echocardiography. Myocardial samples were obtained for histologic and molecular evaluation. For cellular evaluation, fibrosis-induced cardiomyoblast (H9C2) cells were obtained, and transfection was performed for mechanism analysis (serum and glucocorticoid-regulated kinase 1 (SGK1) signaling analysis). Results: The diabetes+dapagliflozin group showed attenuation of diastolic dysfunction compared with the diabetes group. Dapagliflozin inhibited myocardial fibrosis via inhibition of SGK1 and epithelial sodium channel (ENaC) protein, which was observed both in myocardial tissue and H9C2 cells. In addition, dapagliflozin showed an anti-inflammatory effect and ameliorated mitochondrial disruption. Inhibition of SGK1 expression by siRNA decreased and ENaC and Na+/H+ exchanger isoform 1 (NHE1) expression was confirmed as significantly reduced as siSGK1 in the diabetes+dapagliflozin group. Conclusions: Dapagliflozin attenuated left ventricular diastolic dysfunction and cardiac fibrosis via regulation of SGK1 signaling. Dapagliflozin also reduced macrophages and inflammatory proteins and ameliorated mitochondrial disruption. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Benzhydryl Compounds / pharmacology | - |
dc.subject.MESH | Benzhydryl Compounds / therapeutic use | - |
dc.subject.MESH | Diabetes Mellitus* | - |
dc.subject.MESH | Fibrosis | - |
dc.subject.MESH | Glucosides / pharmacology | - |
dc.subject.MESH | Glucosides / therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Rabbits | - |
dc.subject.MESH | Sodium-Glucose Transporter 2 Inhibitors* / pharmacology | - |
dc.subject.MESH | Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use | - |
dc.title | Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seul-Gee Lee | - |
dc.contributor.googleauthor | Darae Kim | - |
dc.contributor.googleauthor | Jung-Jae Lee | - |
dc.contributor.googleauthor | Hyun-Ju Lee | - |
dc.contributor.googleauthor | Ro-Kyung Moon | - |
dc.contributor.googleauthor | Yong-Joon Lee | - |
dc.contributor.googleauthor | Seung-Jun Lee | - |
dc.contributor.googleauthor | Oh-Hyun Lee | - |
dc.contributor.googleauthor | Choongki Kim | - |
dc.contributor.googleauthor | Jaewon Oh | - |
dc.contributor.googleauthor | Chan Joo Lee | - |
dc.contributor.googleauthor | Yong-Ho Lee | - |
dc.contributor.googleauthor | Seil Park | - |
dc.contributor.googleauthor | Ok-Hee Jeon | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Geu-Ru Hong | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.identifier.doi | 10.1186/s12916-022-02485-z | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A01522 | - |
dc.contributor.localId | A02395 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A04386 | - |
dc.contributor.localId | A02927 | - |
dc.contributor.localId | A05164 | - |
dc.contributor.localId | A03238 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A02984 | - |
dc.contributor.localId | A05997 | - |
dc.relation.journalcode | J00364 | - |
dc.identifier.eissn | 1741-7015 | - |
dc.identifier.pmid | 36068525 | - |
dc.subject.keyword | Diabetes mellitus | - |
dc.subject.keyword | Heart failure | - |
dc.subject.keyword | Left ventricular diastolic function | - |
dc.subject.keyword | Sodium-glucose cotransporter 2 inhibitor | - |
dc.contributor.alternativeName | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 박세일 | - |
dc.contributor.affiliatedAuthor | 오재원 | - |
dc.contributor.affiliatedAuthor | 이용호 | - |
dc.contributor.affiliatedAuthor | 홍그루 | - |
dc.contributor.affiliatedAuthor | 이승준 | - |
dc.contributor.affiliatedAuthor | 이오현 | - |
dc.contributor.affiliatedAuthor | 이찬주 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 이용준 | - |
dc.contributor.affiliatedAuthor | 전옥희 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 309 | - |
dc.identifier.bibliographicCitation | BMC MEDICINE, Vol.20(1) : 309, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.